mTOR pathway in renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 2, 2008, Pages 283-292

  Hann, Sara C ^a   Heathcote, Samuel A ^b   Kim, William Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoxia inducible factor; mTOR; mTOR inhibitor; Rapamycin; Renal cell carcinoma; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AP 23573; EVEROLIMUS; FKBP12; GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HAMARTIN; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INSENSITIVE COMPLEX PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN SENSITIVE COMPLEX PROTEIN; RAPAMYCIN; RAS PROTEIN; RHEB PROTEIN; RIBOSOME PROTEIN; S6 KINASE; TEMSIROLIMUS; TUBERIN; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CELL STRESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOWN REGULATION; DRUG INHIBITION; DRUG TARGETING; ENZYME REGULATION; HUMAN; HYPOXIA; KIDNEY CARCINOMA; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RIBOSOME SUBUNIT; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 40749163030     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.2.283     Document Type: Review

References (88)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo). 28, 721-726 (1975).
2. Heitman J, Movva NR, Hall MN. Targets fer cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909 (1991).
3. 3K and mTOR signalling controls tumour cell growth. Nature 441, 424-430 (2006).
4. Choi KM, McMahon LP, Lawrence JC Jr. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J. Biol. Chem. 278, 19667-19673 (2003).
5. Hara. K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189 (2002).
6. Nojima H, Tokunaga C, Eguchi S et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278, 15461-15464 (2003).
7. Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797-806 (2003).
8. Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
9. Loewith R, Jacinto E, Wullschleger S et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468 (2002).
10. Sarbassov DD, Guertin DA. Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
11. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates: the cytoskeleton. Curr. Biol. 14, 1296-1302 (2004).
12. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128 (2004).
13. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006).
14. Murakami M, Ichisaka. T, Maeda M et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24, 6710-6718 (2004).
15. Gangloff YG, Mueller M, Dann SG et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24, 9508-9516 (2004).
16. Martin PM, Sutherland AE. Exogenous amino acids regulate trophectoderm differentiation in the mouse blastocyst through, an mTOR-dependent pathway. Dev. Biol. 240, 182-193 (2001).
17. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14, 2689-2694 (2000).
18. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev. 14, 2712-2724 (2000).
19. Colombani J, Raisin S, Pantalacci S, Radimerski T, Montagne J, Leopold P. A nutrient sensor mechanism controls Drosophila growth. Cell 114, 739-749 (2003).
20. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69, 1227-1236 (1992).
21. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358, 70-73 (1992).
22. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257, 973-977 (1992).
23. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 16, 78-84 (2006).
24. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem. 267, 6321-6330 (2000).
25. Mendez R, Myers MG Jr, White MF, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidy linositol 3-kinase. Mol. Cell. Biol. 16, 2857-2864 (1996).
26. Rosenwald IB, Kaspar R, Rousseau D et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 270, 21176-21180 (1995).
27. Li Y, Corradetti MN, Inoki IC, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29, 32-38 (2004).
28. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5, 578-581 (2003).
29. Li Y, Inold K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell Biol. 24,7965-7975 (2004).
30. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 (2002).
31. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945 (2004).
32. Gao X, Zhang Y, Arrazola P et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699-704 (2002).
33. Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Mol. Chem. 280, 18717-18727 (2005).
34. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702-713 (2005).
35. Nobukuni T. Joaquin M, Roccio M et al. Amino acids mediate mTOR/ raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl Acad. Sci. USA 102,14238-14243 (2005).
36. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280, 33076-33082 (2005).
37. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
38. Shaw RJ, Bardeesy N, Manning BD et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99 (2004).
39. Corradetti MN, Inoki Y, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18, 1533-1538 (2004).
40. Reiling JH, Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18, 2879-2892 (2004).
41. Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004).
42. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin. Oncol. 22, 4991-5004 (2004).
43. Semenza GL. HIF-1 and mechanisms of hypoxia. sensing. Curr. Opin. Cell Biol. 13, 167-171 (2001).
44. 2 sensing. Science 292, 464-468 (2001).
45. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
46. Kumar SM, Yu H, Edwards R et al. Mutant V600E BRAF increases hypoxia inducible factor-1α expression in melanoma. Cancer Res. 67, 3177-3184 (2007).
47. Sodhi A. Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287, 292-300 (2001).
48. Blancher C, Moore JW Robertson N, Harris AL. Effects of ras and von Hippel-Linclau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 61, 7349-7355 (2001).
49. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).
50. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
51. Maranchie JK, Visselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002).
52. - tumors. Mol. Cancer Res. 2, 89-95 (2004).
53. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
54. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12, 122-127 (2006).
55. Treiris C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975-27981 (2002).
56. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158 (2003).
57. Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES. Renal lesion growth in children with tuberous sclerosis complex. J. Urol. 160, 141-145 (1998).
58. Stillwell TJ, Gomez MR, Kelalis PP. Renal lesions in tuberous sclerosis. J. Urol. 138, 477-481 (1987).
59. Cook JA, Oliver K, Mueller RF, Sampson J. A cross sectional study of renal involvement in tuberous sclerosis. J. Med. Genet. 33, 480-484 (1996).
60. Alimov A, Li C, Gizatullin R et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 19, 3841-3846 (1999).
61. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer 91, 219-224 (2001).
62. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol. 84, 166-172 (2003).
63. Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 173, 1496-1501 (2005).
64. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 99, 53-57 (2002).
65. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 16, 928-933 (2005).
66. Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol. 169, 710-713 (2003).
67. Fujita J, Kraus MH, Onoue H et al. Activated H-ras oncogenes in human kidney tumors. Cancer Res. 48, 5251-5255 (1988).
68. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP. Infrequent ras oncogene point mutations in renal cell carcinoma. J. Urol. 143, 175-178 (1990).
69. Rochlitz CF, Peter S, Willroth G et al.. Mutations in the ras protooncogenes are rare events in renal cell cancer. Eur. J. Cancer 28, 333-336 (1992).
70. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res. 54, 3682-3685 (1994).
71. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer 94, 212-217 (2001).
72. Dreijerink K, Braga E, Kuzmin I et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl Acad. Sci. USA 98, 7504-7509 (2001).
73. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65, 3497-3508 (2005).
74. -/- renal cell carcinoma cells. J. Biol. Chem. 278, 44966-44974 (2003).
75. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58, 226-231 (1998).
76. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I- mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J. Biol. Chem. 275, 20700-20706 (2000).
77. Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res. 13, S671-S679 (2007).
78. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 6, 637-645 (2006).
79. Toro JR, Nickerson ML, Wei MH et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95-106 (2003).
80. Pollard PJ, Spencer-Dene B, Shukla D et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311-319 (2007).
81. Nickerson ML, Warren MB, Toro JR et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157-164 (2002).
82. Gad S, Lefevre SH, Khoo SK et al. Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma. Br. J. Cancer 96, 336-340 (2007).
83. Baba M, Hong SB, Sharma N et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl Acad Sci. USA 103, 15552-15557 (2006).
84. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058 (2005).
85. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349 (2006).
86. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
87. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
88. Dutcher J, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv rcc) receiving temsirolimus (temsr) or interferon-α (IFN). J. Clin. Oncol. ASCO Annual Meeting Proceedings Part 1. 25, S18 (2007) (Abstract 5033).